Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home Know-who Know-how Directory From A to Z Nycomed bv

Nycomed bv

Business focus: Pain, respiratory, cardiology, gastroenterology, tissue management, osteoporose. New products are sourced both from our own research and from business partners at various stages in development.

LogoNycomedBV

Nycomed bv
Jupiterstraat 250
2132 HK Hoofddorp
Website Nycomed bv
E-mail Nycomed bv
T +31 (0)23 566 87 00
F +31 (0)23 566 88 00

Employees in Amsterdam: 120
Employees in R&D: 0
Year of foundation: 1874


Company profile

Nycomed is a pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region, Nycomed has a presence in about 50 markets worldwide. Privately owned, the combinedgroup had annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results). For more information visit www.nycomed.com. Nycomed in the Netherlands is located in Hoofddorp, it employs over 120 people.

Alliances

CROs, Biotechnology, service industry etc

Keywords

  • Business development opportunities
  • Pipeline sourcing
  • Inlicensing
  • Partnerships
  • Strategic alliances

Document Actions

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...